E. NELLESSEN ET COLL.
Rev Med Liege 2006; 61 : 3 : 154-158
158
B
IBLIOGRAPHIE
1. Cleland JG, Gemmell I, Khand A et al.— Is the progno-
sis of heart failure improving ? Eur J Heart Fail, 1999,
1, 229-241.
2. Kalra PR, Bolger AP, Francis DP et al.— Effect of ane-
mia on exercise tolerance in chronic heart failure in men.
Am J Cardiol, 2003, 91, 888-891.
3. Felker GM, Adams KF Jr, Gattis WA et al.— Anemia as
a risk factor and therapeutic target in heart failure. J Am
Coll Cardiol, 2004, 44, 959-966.
4. Silverberg DS, Wexler D, Blum M et al.— The use of
subcutaneous erythropoietin and intravenous iron for the
treatment of the anemia of severe, resistant congestive
heart failure improves cardiac and renal function and
functional cardiac class, and markedly reduces hospita-
lizations. J Am Coll Cardiol, 2000, 35, 1737-1744.
5. Anand I, McMurray JJ, Whitmore J et al.— Anemia and
its relationship to clinical outcome in heart failure. Cir-
culation, 2004, 110, 149-154.
6. Haber HL, Leavy JA, Kessler PD et al.— The erythro-
cyte sedimentation rate in congestive heart failure. N
Engl J Med, 1991, 324, 353-8.
7. Ezekowitz JA, McAlister FA, Armstrong PW.— Anemia
is common in heart failure and is associated with poor
outcomes : insights from a cohort of 12065 patients with
new onset heart failure. Circulation, 2003, 107, 223-
225.
8. Silverberg DS.— Outcomes of anaemia management in
renal insufficiency and cardiac disease. Nephrol Dial
Transplant, 2003, 18, (Suppl 2), 7-12.
9. MacDougall IC, Cooper AC.— Erythropoietin resis-
tance : the role of inflammation and pro-inflammatory
cytokines. Nephrol Dial Transplant, 2002, 17,(Suppl
11), 39-43.
10. Kannel WB.— Epidemiology and prevention of cardiac
failure : Framingham study insights. Eur Heart J, 1987,
8, (Suppl F), 23-26.
11. Kannel WB.— Epidemiology and prevention of cardiac
failure : Framingham study insights. Eur Heart J, 1998,
8, 23-29.
12. Al-Ahmad A, Rand WM, Manjunath G et al.— Reduced
kidney function and anemia as risk factors for mortality
in patients with left ventricular dysfunction. J Am Coll
Cardiol, 2001, 38, 955-962.
13. Sharma R, Francis DP, Pitt B et al.— Haemoglobin pre-
dicts survival in patients with chronic heart failure : a
substudy of the Elite II trial. Eur Heart J, 2004, 25,
1021-1028.
14. Horwich TB, Fonarow GC, Hamilton MA et al.— Ane-
mia is associated with worse symptoms, greater impair-
ment in functional capacity and a significant increase in
mortality in patients with advanced heart failure. J Am
Coll Cardiol, 2002, 39, 1780-1786.
15. Felker GM, Gattis WA, Leimberger JD et al.— Useful-
ness of anemia as a predictor of death and rehospitaliza-
tion in patients with decompensated heart failure. Am J
Cardiol, 2003, 92, 625-628.
16. Winearls CG.— Recombinant human erythropoietin :
10 years of clinical experience. Nephrol Dial Transplant,
1998, 13, (Suppl 2, 3-8.
17. Magnanti M, Gandini O, Giuliani L et al.— Erythro-
poietin expression in primary rat Sertoli and peritubular
myoid cells. Blood, 2001, 98, 2872-2874.
18. Welch HG, Meehan KR, Goodnough LT.— Prudent stra-
tegies for elective red blood cell transfusion. Ann Intern
Med, 1992, 116, 393-402.
19. Goodnough LT, Brecher ME, Kanter MH et al.— Trans-
fusion medicine : first of two parts-blood transfusion. N
Engl J Med, 1999, 340, 438-447.
20. Fishbane S, Frei GL, Maesaka J.— Reduction in recom-
binant human erythropoietin doses by the use of chronic
intravenous iron supplementation. Am J Kidney Dis,
1995, 26, 41-46.
21. Macdougall IC, Tucker B, Thompson J et al.— A rando-
mized controlled study of iron supplementation in
patients treated with erythropoietin. Kidney Int, 1996,
50, 1694-1699.
22. Goldberg N, Lundin AP, Delano B et al.— Changes in
left ventricular size, wall thickness and function in ane-
mic patients treated with recombinant human erythro-
poietin. Am Heart J, 1992, 124, 424-427.
23. Silverberg DS, Wexler D, Sheps D et al.— The effect of
correction of mild anemia in severe, resistant congestive
heart failure using subcutaneous erythropoietin and
intravenous iron : a randomized controlled study. J Am
Coll Cardiol, 2001, 37, 1775-1780.
24. Mancini DM, Katz SD, Lamanca J et al.— Effect of ery-
thropoietin on exercise capacity in patients with mode-
rate to severe chronic heart failure. Circulation, 2003,
107, 294-299.
25. Mann JF.— Hypertension and cardiovascular effects-
long-term safety and potential long-term benefits of r-
HuEPO. Nephrol Dial Transplant, 1995, 10, 80-84.
26. Taylor JE, McLaren M, Henderson IS et al.— Pro-
thrombotic effect of erythropoietin in dialysis patients.
Nephrol Dial Transplant, 1992, 7, 235-239.
27. Felker GM, O’Connor CM.— Inotropic therapy for
heart failure : an evidence-based approach. Am Heart J,
2001, 142, 393-401.
28. Louis A, Cleland JG, Crabbe S et al.— Clinical trials
update: CAPRICORN, COPERNICUS, MIRACLE,
STAF, RITZ-2, RECOVER and RENAISSANCE and
cachexia and cholesterol in heart failure : highlights of
the Scientific Sessions of the American College of Car-
diology, 2001. Eur J Heart Fail, 2001, 3, 381-387.
29. Adams KF, Patterson JH, Pina I et al.— STAMINA-HFP
(Study of Anemia in a Heart Failure Population) registry
: rationale, design and patient characteristics. J Card
Failure, 2003, 9, 73.
30. Masuda S, Nagao M, Sasaki R.— Erythropoietic, neu-
trophilic and angiogenic functions of erythropoietin and
regulation of erythropoietin production. Int J Hematol,
1999, 70, 1-6.
31. Parsa CJ, Matsumoto A, Kim J et al.— A novel protec-
tive effect of erythropoietin in the infarcted heart. J Clin
Invest, 2003, 112, 999-1007.
Les demandes de tirés à part sont à adresser au
Prof. L. Piérard, Service de Cardiologie, CHU Sart
Tilman, 4000 Liège